501 results on '"Halaban, Ruth"'
Search Results
2. Interferon-stimulated neutrophils as a predictor of immunotherapy response
3. Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5
4. Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma
5. A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers.
6. Clonal determinants of organotropism and survival in metastatic uveal melanoma
7. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
8. Author Correction: Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis
9. Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis
10. Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma
11. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
12. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
13. CD4 T cells and toxicity from immune checkpoint blockade
14. Future Perspectives in melanoma research:Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010".
15. Abstract 6670: Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade
16. Supplementary Figure 6 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
17. Supplementary Figure 4 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
18. Supplementary Tables 1-3 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
19. Supplementary Figure 3 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
20. Supplementary Figure 1 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
21. Supplementary Figure 2 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
22. Supplementary Figure 1 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
23. Supplementary Table 4 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
24. Data from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
25. Data from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
26. Supplementary Table 5 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
27. Data from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
28. Supplemental Material, Supplementary Figures 1 and 2, Supplemental Tables 1 - 8 from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
29. Supplementary Figure 5 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
30. Supplementary Table 6 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
31. Supplementary Figure 7 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
32. Supplementary Table Legends 1-6, Figure Legend 1 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
33. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
34. Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas
35. Endoplasmic Reticulum Retention Is a Common Defect Associated with Tyrosinase-Negative Albinism
36. Identification of Morc (Microrchidia), a Mutation that Results in Arrest of Spermatogenesis at an Early Meiotic Stage in the Mouse
37. Early B cell changes predict autoimmunity following combination immune checkpoint blockade
38. Chymase Cleavage of Stem Cell Factor Yields a Bioactive, Soluble Product
39. Aberrant Retention of Tyrosinase in the Endoplasmic Reticulum Mediates Accelerated Degradation of the Enzyme and Contributes to the Dedifferentiated Phenotype of Amelanotic Melanoma Cells
40. Supplementary Figure S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
41. Supplementary Figure Legends from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
42. Supplementary Table S3 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
43. Supplementary Figures S1-S5 from Plasma Markers for Identifying Patients with Metastatic Melanoma
44. Supplementary Materials and Methods from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
45. Supplementary Table 3 from Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
46. Supplementary Table S2 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
47. Data from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
48. Supplementary Table 1 from Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
49. Supplementary Figures S1-S6 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
50. Supplementary Table 2 from Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.